

THINKING AHEAD IN HER2+ METASTATIC BREAST CANCER

Personalizing Sequencing Strategies and Addressing CNS Burden With State-of-the-Art Targeted Treatments for Second-Line Therapy and Beyond

Suggested Readings

1. Aizer A, Tanguturi SK, Benham G, et al. Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. *J Clin Oncol.* 2025;43(suppl 16):abstr 2011.
2. Harbeck N, Ciruelos E, Jerusalem G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024;30(12):3717-3727.
3. Hurvitz SA, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. *ESMO Open*. 2024;9(5):102924.
4. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. *JAMA Oncol.* 2023;9(2):197-205.
5. NCCN Guidelines. Breast Cancer. Version 4.2025 – April 17, 2025. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
6. NCCN Guidelines. Central Nervous System Cancers. Version 1.2025. June 3, 2025. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
7. O'Brien BJ. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. *J Clin Oncol*. 2024;42(16 suppl): abstract 2018.
8. O'Sullivan C, Ballman KV, McCall LM, et al. Abstract P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. *Clin Cancer Res.* 2025;31 (12_Supplement): P2-10-19.
9. Premji SK and O'Sullivan CC. Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options. *Breast Cancer (Auckl).* 2024;18:11782234241234418.
10. Puri S, Chaudhry A, Bayable A, et al. Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients. *Curr Oncol Rep*. 2023;25(12):1419-1430.
11. Raghavendra AS, Ibrahim NK. Breast Cancer Brain Metastasis: A Comprehensive Review. *JCO Oncol Pract*. 2024;20(10):1348-1359.
12. Vaz Batista M, Pérez-García JM, Garrigós L, et al. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025;6(1):100502.